Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of Friday, August 28, 2026.
EBITDA YIELD
N/A
Market Cap
$358.76B
EBITDA Yield
6.45%
TTM Avg
7.69%
3Y Avg
7.60%
5Y Avg
6.90%
Market Cap
$234.38B
EBITDA Yield
3.85%
TTM Avg
4.60%
3Y Avg
4.67%
5Y Avg
4.83%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Roche Holding AG (RHHBY) | $359.46B | N/A | N/A | N/A | N/A |
| UnitedHealth Group Incorporated (UNH)vs › | $358.76B | 6.45% | 7.69% | 7.60% | 6.90% |
| Merck & Co., Inc. (MRK)vs › | $369.34B | 4.16% | 9.15% | 7.04% | 6.92% |
| AbbVie Inc. (ABBV)vs › | $455.87B | 5.06% | 4.69% | 5.50% | 6.56% |
| AstraZeneca PLC (AZN)vs › | $255.15B | 7.09% | 6.11% | 5.95% | 5.14% |
| Amgen Inc. (AMGN)vs › | $235.85B | 5.33% | 6.53% | 6.23% | 6.74% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $234.38B | 3.85% | 4.60% | 4.67% | 4.83% |
| Novo Nordisk A/S (NVO)vs › | $205.42B | 11.71% | 10.68% | 6.51% | 5.50% |
| Abbott Laboratories (ABT)vs › | $193.04B | 4.81% | 5.26% | 4.89% | 5.31% |
| Gilead Sciences, Inc. (GILD)vs › | $184.82B | 7.86% | 7.25% | 6.52% | 7.72% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
